NCT05671991Active, not recruitingPhase 4
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 14 Dec 2022
- Start date
- 1 Mar 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Yale University
- Diseases
- Chronic kidney disease
- NCT number
- NCT05671991
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 22
- From 1 Mar 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of an SGLT2 inhibitor within the prior 30 days
- 1 or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter
- Contraindication to receiving loop diuretics
Other illness
- History of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months
Lab values
- Anemia with hemoglobin \<8g/dL
Other
- Inability to give written informed consent or follow study protocol
Who the study is looking for
- Patients actively undergoing PD with a reliably functioning PD catheter
- Stable peritoneal dialysis prescription
- PD vintage \> 3 months
- Age \>18 years of age
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yale University Coordinator of this site? Confirm its status | New Haven | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.